$LABT

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On September 22, 2026, Lakewood-Amedex Biotherapeutics Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of the record date of July 30, 2026, there were 2,369,688 shares of

Lakewood-Amedex Biotherapeutics dosed the first patient in a Phase 2a trial for Nu-3, a gel treating mildly infected diabetic foot ulcers. The trial will assess safety, efficacy, and optimal dosage. Results are expected in Q1 2027, with potential Phase 2b advancement if successful. According to the company, Nu-3 aims to reduce antimicrobial resistance by targeting infections locally.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) has dosed the first patient in its Phase 2a clinical trial for Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy of three gel concentrations, with topline data expected in Q1 2027. Nu-3 is part of the company's Bisphosphocin® antimicrobial platform.

Lakewood-Amedex Biotherapeutics (LABT) reported Q2 2026 progress, including Nasdaq listing, $7.5M private placement, and Nu-3 Gel Phase 2a trial prep. The company expanded its IP portfolio and appointed David G. Armstrong as Study Chair. LABT aims to advance Nu-3 for infected diabetic foot ulcers, with clinical trial initiation expected soon.

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and confirmed clinical site readiness to start a Phase 2a trial for Nu-3, a treatment for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy, building on positive preclinical data. The company focuses on addressing antibiotic-resistant bacterial infections with its Bisphosphocin® class of antimicrobials.

A healthcare sector roundup highlights biotech stock moves. Zhongchao (ZCMD) rose about 192% after a 1-for-3 reverse split for Nasdaq compliance. Lakewood-Amedex (LABT) gained about 83% on positive Nu-3 Phase 2-ready updates. Arrowhead (ARWR) jumped about 19% after SHASTA-3/4 topline results for Plozasiran. Other gainers included MSLE, DRIO, and LBRX.

Lakewood-Amedex Biotherapeutics (LABT) said it presented new data on its antimicrobial candidate Nu-3 for infected diabetic foot ulcers. The company reported a high barrier to resistance in serial passage tests and broad in vitro activity against multiple resistant bacteria mechanisms. LABT linked the findings to the National Action Plan discussed at a June 2026 PACCARB meeting. LABT closed at $1.86.

Lakewood-Amedex Biotherapeutics (LABT) shares rose about 108% on Wednesday after the company highlighted new data for its lead antimicrobial candidate, Nu-3, saying it showed a high barrier to bacterial resistance. The stock was quoted around $3.86 on Nasdaq, up about $2.00, after opening at $6.50.

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) said preclinical safety data for its Nu-3 topical gel supported dose selection for an upcoming Phase 2a trial in infected diabetic foot ulcers. The company reported Nu-3 was well tolerated in an FDA-required safety study at higher doses, with low systemic exposure and no wound-healing inhibition. Planned gel concentrations are 2%, 5%, and 10%.